Palatin Technologies

Palatin launches web site in support of phase III program for female sexual dysfunction

Thursday, February 26, 2015

Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, has launched a clinical trial web site ( in support of its phase III reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).

[Read More]

Palatin Technologies reports successful completion of device bioequivalence trial

Tuesday, October 29, 2013

Palatin Technologies has announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its phase II clinical trials, but will use the single-dose disposable autoinjector in its planned phase III clinical trials and for commercialization.

[Read More]